Cyclopharm Partners with US Veterans Health Administration to supply Technegas

Cyclopharm (ASX:CYC) has partnered with the US Veterans Health Administration to supply the pharmaceutical and consumable components of Technegas.

The agreement provides 120 Veterans Affairs hospitals, which have nuclear medicine departments, access to the products immediately.

The interim agreement marks a crucial step towards Cyclopharm's inclusion on the broader US Federal Supply Schedule, which streamlines the procurement process for US federal agencies.

Cyclopharm's CEO, James McBrayer, stated, "Securing this interim agreement is critical for streamlining the United States Federal Government procurement process."

In addition, Cyclopharm has received its first purchase order for Technegas from a Department of Defence hospital.

This progress highlights the company's efforts to expand Technegas implementation across VA, DoD, and Public Health Service networks.

Initial installations at VA, DoD, and PHS sites are expected to begin in the first half of 2025.

The agreement is a key factor for Cyclopharm's US strategy, enhancing care under the PACT Act by providing accurate diagnostic aids for conditions such as COPD and pulmonary fibrosis.

Cyclopharm is a radiopharmaceutical company. The company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector.